Oncotarget

Research Papers:

Identification of a chrXq273 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients

PDF  |  Full Text  |  Supplementary Files  |  How to cite

Oncotarget. 2011; 2:1265-1278. https://doi.org/10.18632/oncotarget.401

Metrics: PDF 3154 views  |  Full Text 4594 views

Marina Bagnoli1,§, Loris De Cecco1,§, Anna Granata1, Roberta Nicoletti1, Edoardo Marchesi1, Paola Alberti1, Barbara Valeri2, Massimo Libra3, Mattia Barbareschi4, Francesco Raspagliesi5, Delia Mezzanzanica1,#, Silvana Canevari1,#

1 Depts. of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

2 Department of Pathology and Oncologic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

3 Department of General Pathology, University of Catania, Italy

4 Department of Pathology, Ospedale Santa Chiara, Trento, Italy

5 Department of Oncologic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

§ equally contributing first authors

# equally contributing last authors

Received: December 23, 2011; Accepted: December 30, 2011; Published: December 31, 2011;

Keywords: advanced-stage ovarian cancer, early relapse, microRNA profiling, miR-506, cisplatin, miR-513a-5p, miR-513b

Correspondence:

Silvana Canevari, email:

Abstract

A major challenge in advanced-stage epithelial ovarian cancer (EOC) is prediction of chemoresistant relapse. Our aim was to identify a microRNA (miRNA) signature associated with early relapse in advanced-stage EOC patients. miRNA expression was assessed by microarray profiling in training (n = 55) and test (n = 30) sets selected on the basis of time to relapse (TTR), followed by internal quantitative reverse transcriptase-PCR validation on a set of 45 consecutive cases unselected for clinical response and external in silico validation on publicly available datasets. Thirty-two differentially expressed miRNAs in early vs. late relapsing patients were identified in the training set. In the test set, 8 of these, belonging to a cluster located on chrXq27.3, were down-modulated in early relapsing patients. Hierarchical clustering of the internal validation set according to chrXq27.3 miRNA expression associated low miRNA expression with shorter TTR (log-rank P=0.00074, HR 2.44). The cluster was an independent prognostic factor in both internal and external validation sets. Forced expression of chrXq27.3-cluster selected miRNAs in human EOC cellular models was associated to reduction of cell proliferation and increased sensitivity to cisplatin. The role of down-modulation of the chrXq27.3 miRNA cluster in early relapse of advanced-stage EOC patients and its association to a reduced sensitivity to chemotherapeutic treatments warrant further investigation.